Physician profile
Mark Kendrick
NPI 1306947452
$988.60
in general payments reported to CMS, 2019-2025
16 companies · $34.23 in 2025
The $34.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $40.74 · 2021: $200 · 2022: $124 · 2023: $129 · 2024: $189 · 2025: $34.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $352.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $207.72 | 2019-2023 | |
| Abbvie INC. | $191.02 | 2021-2023 | |
| Lilly USA, LLC | $119.50 | 2020-2024 | Zepbound, Mounjaro |
| Allergan, INC. | $67.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.52 | 2024-2025 | Airsupra |
| Amgen INC. | $56.89 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $56.55 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $39.82 | 2022-2024 | |
| Novo Nordisk INC | $36.16 | 2021-2023 | Wegovy |
| Glaxosmithkline, LLC. | $34.50 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.85 | 2019-2025 | Jardiance |
| Abbott Laboratories | $23.42 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.41 | 2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $16.25 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $16.18 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.